STAAR Surgical Q2 Sales Hit $93.5M, Swings to Profit on China Surge
STAA sits 47% above its 52-week low of $15.585.
Summary
STAAR Surgical reported Q2 net sales of $93.5 million, up 111% year-over-year, driven by over 100% growth in China. The company swung to a net income of $8.1 million, or $0.16 per share, from a loss a year ago, with gross margin improving to 74.5%. This follows the July 16 pre-announcement of sales exceeding $90 million, but today's release adds full profitability, margin detail, and guidance. Management expects strong ICL demand to continue through 2026, though Q3 China sales will step down from the H1 peak due to a prior one-time order. Tariff-related margin pressure is expected to persist until all China-bound products are manufactured in Switzerland by end-2026.
At the time of this announcement, STAA was trading at $22.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $15.59 to $35.87. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.